These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 29725743)

  • 1. 3T multiparametric MR imaging, PIRADSv2-based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard.
    Asvadi NH; Afshari Mirak S; Mohammadian Bajgiran A; Khoshnoodi P; Wibulpolprasert P; Margolis D; Sisk A; Reiter RE; Raman SS
    Abdom Radiol (NY); 2018 Nov; 43(11):3117-3124. PubMed ID: 29725743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of missed prostate cancer lesions on 3T multiparametric-MRI in 518 patients: based on PI-RADSv2 and using whole-mount histopathology reference.
    Mohammadian Bajgiran A; Afshari Mirak S; Shakeri S; Felker ER; Ponzini D; Ahuja P; Sisk AE; Lu DS; Raman SS
    Abdom Radiol (NY); 2019 Mar; 44(3):1052-1061. PubMed ID: 30460528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
    Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
    J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.
    Vargas HA; Hötker AM; Goldman DA; Moskowitz CS; Gondo T; Matsumoto K; Ehdaie B; Woo S; Fine SW; Reuter VE; Sala E; Hricak H
    Eur Radiol; 2016 Jun; 26(6):1606-12. PubMed ID: 26396111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Pathological Tumor Size in Prostate Cancer Based on Multiparametric Prostate Magnetic Resonance Imaging and Preoperative Findings.
    Pooli A; Johnson DC; Shirk J; Markovic D; Sadun TY; Sisk AE; Mohammadian Bajgiran A; Afshari Mirak S; Felker ER; Hughes AK; Raman SS; Reiter RE
    J Urol; 2021 Feb; 205(2):444-451. PubMed ID: 33026934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three Tesla Multiparametric Magnetic Resonance Imaging: Comparison of Performance with and without Endorectal Coil for Prostate Cancer Detection, PI-RADS™ version 2 Category and Staging with Whole Mount Histopathology Correlation.
    Mirak SA; Shakeri S; Bajgiran AM; Felker ER; Sung KH; Asvadi NH; Khoshnoodi P; Markovic D; Ponzini D; Ahuja P; Sisk A; Reiter RE; Lu D; Raman SS
    J Urol; 2019 Mar; 201(3):496-502. PubMed ID: 30273608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detectability of prostate cancer in different parts of the gland with 3-Tesla multiparametric magnetic resonance imaging: correlation with whole-mount histopathology.
    Ito K; Furuta A; Kido A; Teramoto Y; Akamatsu S; Terada N; Yamasaki T; Inoue T; Ogawa O; Kobayashi T
    Int J Clin Oncol; 2020 Apr; 25(4):732-740. PubMed ID: 31792635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Prostate Imaging Reporting and Data System Version 2 Sufficiently Discovering Clinically Significant Prostate Cancer? Per-Lesion Radiology-Pathology Correlation Study.
    Lee MS; Moon MH; Kim YA; Sung CK; Woo H; Jeong H; Son H
    AJR Am J Roentgenol; 2018 Jul; 211(1):114-120. PubMed ID: 29702017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer.
    Seo JW; Shin SJ; Taik Oh Y; Jung DC; Cho NH; Choi YD; Park SY
    AJR Am J Roentgenol; 2017 Jul; 209(1):W1-W9. PubMed ID: 28418690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
    Lim CS; McInnes MDF; Flood TA; Breau RH; Morash C; Thornhill RE; Schieda N
    AJR Am J Roentgenol; 2017 May; 208(5):1037-1044. PubMed ID: 28267359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.
    Woo S; Kim SY; Lee J; Kim SH; Cho JY
    Eur Radiol; 2016 Oct; 26(10):3580-7. PubMed ID: 26847042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
    Hosseiny M; Shakeri S; Felker ER; Lu D; Sayre J; Ahuja P; Raman SS
    AJR Am J Roentgenol; 2020 Sep; 215(3):660-666. PubMed ID: 32755166
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
    Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
    Krishna S; McInnes M; Lim C; Lim R; Hakim SW; Flood TA; Schieda N
    AJR Am J Roentgenol; 2017 Dec; 209(6):W365-W373. PubMed ID: 28981356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of PI-RADSv2 with multiparametric MRI in determining who needs active surveillance or definitive treatment according to PRIAS.
    Park JJ; Park BK
    J Magn Reson Imaging; 2017 Jun; 45(6):1753-1759. PubMed ID: 27783436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.
    Radtke JP; Schwab C; Wolf MB; Freitag MT; Alt CD; Kesch C; Popeneciu IV; Huettenbrink C; Gasch C; Klein T; Bonekamp D; Duensing S; Roth W; Schueler S; Stock C; Schlemmer HP; Roethke M; Hohenfellner M; Hadaschik BA
    Eur Urol; 2016 Nov; 70(5):846-853. PubMed ID: 26810346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic performance and reproducibility of T2w based and diffusion weighted imaging (DWI) based PI-RADSv2 lexicon descriptors for prostate MRI.
    Benndorf M; Hahn F; Krönig M; Jilg CA; Krauss T; Langer M; Dovi-Akué P
    Eur J Radiol; 2017 Aug; 93():9-15. PubMed ID: 28668436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance.
    Curci NE; Lane BR; Shankar PR; Noyes SL; Moriarity AK; Kubat A; Brede C; Montgomery JS; Auffenberg GB; Miller DC; Montie JE; George AK; Davenport MS
    Urology; 2018 Jun; 116():137-143. PubMed ID: 29653121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic contrast-enhanced (DCE) MR imaging: the role of qualitative and quantitative parameters for evaluating prostate tumors stratified by Gleason score and PI-RADS v2.
    Afshari Mirak S; Mohammadian Bajgiran A; Sung K; Asvadi NH; Markovic D; Felker ER; Lu D; Sisk A; Reiter RE; Raman SS
    Abdom Radiol (NY); 2020 Jul; 45(7):2225-2234. PubMed ID: 31549211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.